A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
- 219 Downloads
Background 2-methoxyestradiol (2ME2) is an estradiol-17β metabolite with antiproliferative and antiangiogenic activities. ENMD-1198 is an analog of 2ME2 which was developed to decrease the metabolism and increase both the bioavailability and antitumor activities of the parent molecule. This first-in-human phase I study evaluated the tolerability, pharmacokinetics and preliminary evidence of activity of ENMD-1198 in advanced cancer patients. Methods Eligible patients received ENMD-1198 orally once daily in Part A (standard 3 + 3 dose escalation design), or in Part B (accelerated dose escalation design). Cycle 1 consisted of 28 days daily dosing followed by a 14-(Part A) or 7-(Part B) day observation period, then continuously in 28 day cycles thereafter. Results A total of 29 patients were enrolled in 12 dose cohorts (5 to 550 mg/m2/d). The most common drug-related toxicities were Grade 1/2 fatigue (55%), nausea and vomiting (37%), and constipation (34%). Two DLTs (Grade 4 neutropenia) occurred at 550 mg/m2/day, and 425 mg/m2/d was declared the maximum tolerated dose. ENMD-1198 was absorbed rapidly with a Tmax of 1–2 h. Exposure to ENMD-1198 (Cmax and AUC0–24 hr) increased linearly with dose. The mean terminal half-life was 15 h. A 3-fold accumulation was found after multiple doses. Five patients achieved stabilization of disease for at least 2 cycles, three of whom (with neuroendocrine carcinoma of pancreas, prostate cancer and ovarian cancer) demonstrated prolonged stabilization ranging from 8–24.5 cycles. Conclusion ENMD-1198 is well-tolerated with a pharmacokinetic exposure profile compatible with once daily dosing. The recommended phase II dose of ENMD-1198 is 425 mg/m2/d. Early evidence of prolonged disease stabilization in pre-treated patients suggests ENMD-1198 is worthy of additional investigation.
KeywordsENMD-1198 Phase I Pharmacokinetics
Vascular endothelial growth factor
Dose limiting toxicity
Maximum tolerated dose
Liquid chromatography-tandem mass spectrometry
Eastern Cooperative Oncology Group
- CTCAE v3
Common Terminology Criteria for Adverse Events, Version 3.0
Response Evaluation Criteria In Solid Tumors
Mark Morrow (Clinical Study Co-ordination), University of Colorado Cancer Center.
- 8.Fogler WE, Volker K, Swartz GM et al (2006) The antitumor activity of 2-methoxyestradiol is maximized by maintaining a threshold concentration over a 24-hour dosing interval. Proceedings of the AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics, Washington DC B180:173Google Scholar
- 14.Burke PA, Chen XR, Waters CL et al (2006) In vitro and in vivo mechanisms of action for the antitumor activity of the microtubule destabilizing agent ENMD-1198 include inhibition of HIF-1α, NF-κB and Stat3. AACR Abstract #491. http://aacrmeetingabstracts.org/cgi/content/abstract/2006/1/116
- 15.LaVallee TM, Swartz GM, Strawn S et al (2005) Antitumor activity and preclinical toxicity for microtubule destabilizing agent ENMD-1198. Proceedings of the AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, B240, page 188Google Scholar